• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

V2 血管加压素受体突变。

V2 vasopressin receptor mutations.

机构信息

Department of Endocrinology and Nephrology, The University of Tokyo, Tokyo, Japan.

Department of Endocrinology and Nephrology, The University of Tokyo, Tokyo, Japan.

出版信息

Vitam Horm. 2020;113:79-99. doi: 10.1016/bs.vh.2019.08.012. Epub 2019 Sep 13.

DOI:10.1016/bs.vh.2019.08.012
PMID:32138955
Abstract

V2 vasopressin receptor (V2R) is a member of the G protein-coupled receptor (GPCR) family in which many disease-causing mutations have been identified and thus generated much interest. Loss-of-function V2R mutations cause nephrogenic diabetes insipidus (NDI) whereas gain-of-function mutations cause nephrogenic syndrome of inappropriate antidiuresis (NSIAD). The mechanisms underlying a V2R loss-of-function can be theoretically classified as either protein expression, localization (ER retention) or functional disorders. Functional analyses have revealed however that these mechanisms are likely to be complex. Strikingly, V2R mutations at the same site can result in opposite phenotypes, e.g., R137H and R137L/C cause NDI and NSIAD, respectively. These findings support the notion that the constitutive activation of GPCRs might be often associated with their instability and denaturation. Thus, functional analysis of disease-causing V2R mutations may not only reveal potential new treatment strategies using pharmacochaperones for NDI and inverse agonists for NSIAD, but also provide a greater understanding of the physiological functions of GPCRs and highlight the new paradigms, i.e., biased agonism and protean agonism.

摘要

V2 血管加压素受体 (V2R) 是 G 蛋白偶联受体 (GPCR) 家族的成员,该家族中已发现许多致病突变,因此引起了广泛关注。V2R 的功能丧失性突变会导致肾性尿崩症 (NDI),而获得性功能的突变会导致肾性尿崩症伴抗利尿激素不适当分泌 (NSIAD)。V2R 功能丧失的理论机制可分为蛋白表达、定位(内质网保留)或功能障碍。然而,功能分析表明这些机制可能很复杂。引人注目的是,相同位置的 V2R 突变会导致相反的表型,例如,R137H 和 R137L/C 分别导致 NDI 和 NSIAD。这些发现支持这样一种观点,即 GPCR 的组成性激活可能常常与它们的不稳定性和变性有关。因此,对致病 V2R 突变的功能分析不仅可能揭示用于 NDI 的药理学伴侣和用于 NSIAD 的反向激动剂的潜在新治疗策略,还可能提供对 GPCR 生理功能的更深入了解,并强调新的范例,即偏性激动和多变激动。

相似文献

1
V2 vasopressin receptor mutations.V2 血管加压素受体突变。
Vitam Horm. 2020;113:79-99. doi: 10.1016/bs.vh.2019.08.012. Epub 2019 Sep 13.
2
Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.血管加压素 2 型受体替换(R137H/C/L)导致的肾性尿崩症和抗利尿激素不适当分泌综合征的功能特征:对治疗的影响。
Mol Pharmacol. 2010 May;77(5):836-45. doi: 10.1124/mol.109.061804. Epub 2010 Feb 16.
3
Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V).鉴定三种血管升压素受体 2 变体:一种明显的多态性(V266A)和两种失活突变(R181C 和 M311V)。
PLoS One. 2013 Jun 6;8(6):e65885. doi: 10.1371/journal.pone.0065885. Print 2013.
4
V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.V2 血管加压素受体 (V2R) 突变导致部分肾性尿崩症,突显了 V2R 拮抗剂的多变激动作用。
J Biol Chem. 2012 Jan 13;287(3):2099-106. doi: 10.1074/jbc.M111.268797. Epub 2011 Dec 5.
5
Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.对导致部分性肾性尿崩症的V2血管加压素受体(V2R)突变的分析凸显了一种非肽类V2R激动剂的可持续信号传导。
J Biol Chem. 2016 Oct 21;291(43):22460-22471. doi: 10.1074/jbc.M116.733220. Epub 2016 Sep 6.
6
Nephrogenic syndrome of inappropriate antidiuresis: a novel disorder in water balance in pediatric patients.肾源性抗利尿激素分泌不当综合征:小儿患者水平衡的一种新病症。
Am J Med. 2006 Jul;119(7 Suppl 1):S54-8. doi: 10.1016/j.amjmed.2006.05.008.
7
[Nephrogenic syndrome of inappropriate antidiuresis].肾源性抗利尿激素分泌异常综合征
Pan Afr Med J. 2019 Apr 29;32:210. doi: 10.11604/pamj.2019.32.210.6006. eCollection 2019.
8
Novel signalling pathways in nephrogenic syndrome of inappropriate antidiuresis: functional implication of site-specific AQP2 phosphorylation.特发性抗利尿激素分泌不当综合征中的新型信号通路:特定部位 AQP2 磷酸化的功能意义。
J Physiol. 2024 Jul;602(13):3169-3189. doi: 10.1113/JP284039. Epub 2023 Mar 14.
9
Gain-of-function mutations of the V2 vasopressin receptor in nephrogenic syndrome of inappropriate antidiuresis (NSIAD): a cell-based assay to assess constitutive water reabsorption.血管加压素受体 2 功能获得性突变与抗利尿激素不适当分泌综合征(NSIAD):一种评估水持续重吸收的基于细胞的检测方法。
Pflugers Arch. 2019 Oct;471(10):1291-1304. doi: 10.1007/s00424-019-02307-x. Epub 2019 Sep 5.
10
Nephrogenic syndrome of inappropriate antidiuresis (NSIAD): a paradigm for activating mutations causing endocrine dysfunction.肾源性抗利尿激素分泌不当综合征(NSIAD):激活突变导致内分泌功能障碍的范例。
Pediatr Endocrinol Rev. 2006 Dec;4 Suppl 1:66-70.

引用本文的文献

1
A Novel Pathogenic Variant of the Gene Leading to Arginine Vasopressin Resistance Since the Neonatal Period.一种自新生儿期起导致抗精氨酸加压素的该基因的新型致病变异。
Genes (Basel). 2025 Aug 21;16(8):989. doi: 10.3390/genes16080989.
2
Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment.对帕西瑞肽诱导高血糖症中GLP-1和胰岛素分泌机制的深入了解凸显了靶向Gs的糖尿病治疗的有效性。
Sci Rep. 2025 Mar 19;15(1):9494. doi: 10.1038/s41598-025-90896-2.
3
Therapeutic potentials of nonpeptidic V2R agonists for partial cNDI-causing V2R mutants.
非肽类 V2R 激动剂治疗部分 cNDI 致病 V2R 突变体的潜力。
PLoS One. 2024 May 15;19(5):e0303507. doi: 10.1371/journal.pone.0303507. eCollection 2024.
4
Pro-haemostatic effect of DDAVP is partially derived through non-classical (CD14 /CD16 ) monocytes residing the spleen.DDAVP 的促凝作用部分来源于脾脏中存在的非经典(CD14/CD16)单核细胞。
J Cell Mol Med. 2023 Jan;27(1):30-35. doi: 10.1111/jcmm.17606. Epub 2022 Dec 7.
5
G protein-coupled receptors in cochlea: Potential therapeutic targets for hearing loss.耳蜗中的G蛋白偶联受体:听力损失的潜在治疗靶点。
Front Mol Neurosci. 2022 Oct 12;15:1028125. doi: 10.3389/fnmol.2022.1028125. eCollection 2022.
6
Structural and Functional Diversity of Animal Toxins Interacting With GPCRs.与G蛋白偶联受体相互作用的动物毒素的结构与功能多样性
Front Mol Biosci. 2022 Feb 7;9:811365. doi: 10.3389/fmolb.2022.811365. eCollection 2022.
7
Prediction of molecular interactions and physicochemical properties relevant for vasopressin V2 receptor antagonism.预测与血管加压素 V2 受体拮抗作用相关的分子相互作用和物理化学性质。
J Mol Model. 2022 Jan 7;28(2):31. doi: 10.1007/s00894-021-05022-6.
8
Clinical and Functional Characterization of a Novel Mutation in Causing Nephrogenic Diabetes Insipidus in a Four-Generation Chinese Family.一个四代中国家系中导致肾性尿崩症的新突变的临床和功能特征分析
Front Pediatr. 2021 Dec 9;9:790194. doi: 10.3389/fped.2021.790194. eCollection 2021.
9
Functional characterization of a loss-of-function mutant I324M of arginine vasopressin receptor 2 in X-linked nephrogenic diabetes insipidus.I324M 缺失功能突变的精氨酸血管加压素受体 2 对 X 连锁性肾性尿崩症的功能特征分析。
Sci Rep. 2021 May 26;11(1):11057. doi: 10.1038/s41598-021-90736-z.
10
Valine-279 Deletion-Mutation on Arginine Vasopressin Receptor 2 Causes Obstruction in G-Protein Binding Site: A Clinical Nephrogenic Diabetes Insipidus Case and Its Sub-Molecular Pathogenic Analysis.精氨酸加压素受体2上的缬氨酸279缺失突变导致G蛋白结合位点受阻:一例临床肾性尿崩症病例及其亚分子致病分析。
Biomedicines. 2021 Mar 15;9(3):301. doi: 10.3390/biomedicines9030301.